NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.